ACHK.F Stock Overview
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Achiko AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0026 |
| 52 Week High | US$0.044 |
| 52 Week Low | US$0.0026 |
| Beta | -0.70 |
| 11 Month Change | 0% |
| 3 Month Change | -27.78% |
| 1 Year Change | n/a |
| 33 Year Change | -99.42% |
| 5 Year Change | n/a |
| Change since IPO | -99.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACHK.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how ACHK.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ACHK.F performed against the US Market.
Price Volatility
| ACHK.F volatility | |
|---|---|
| ACHK.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACHK.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ACHK.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 10 | Steven Goh | www.achiko.com |
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. The company’s lead product is AptameX, a rapid test that uses DNA aptamers instead of antigens to detect the SARS-CoV-2 virus. It also offers Teman Sehat, a mobile check-in and passport application.
Achiko AG Fundamentals Summary
| ACHK.F fundamental statistics | |
|---|---|
| Market cap | US$58.06k |
| Earnings (TTM) | -US$6.86m |
| Revenue (TTM) | US$24.60k |
15.3x
P/S Ratio-0.1x
P/E RatioIs ACHK.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHK.F income statement (TTM) | |
|---|---|
| Revenue | US$24.60k |
| Cost of Revenue | US$19.31k |
| Gross Profit | US$5.29k |
| Other Expenses | US$6.86m |
| Earnings | -US$6.86m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 21.51% |
| Net Profit Margin | -27,885.01% |
| Debt/Equity Ratio | -64.4% |
How did ACHK.F perform over the long term?
See historical performance and comparison